Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Fine-Tuning = 72%.
View:
Post by wildbird1 on Jun 01, 2023 9:12am

Fine-Tuning = 72%.

If like me you have difficulty to understand the data, just keep in mind one thing, with each update the data are getting better and better.
Yes, getting FDA approval is a slow process, and TLT is slow, or shall we say TLT is very carefull not to over do it.

Although we would like the process to go faster, fast is not always a good idea.
Look at ImmunityBio, they received BTD for N-803+BCG, and they had better results than TLT, now the FDA has stopped the approval process, because of manufacturing issue. It could be years before N-803+BCG approval.
Nobody want TLT to rush into such a mess.

Dr.Kulkarni & 72% Fine-Tuning.
One very important quote that went unnoticed in the last video by Ashish Kamat & Dr.Girish Kulkarni(provided by livermore2).
Dr.Kulkarni said" So there is a learning curve to it. With any new procedure, it will take time to learn that. But now we've got it down to a "fine art".

In short, what Dr.Kulkarni is saying, we at TLT are getting damn good at fine-tuning this treatment. If Dr.Kulkarni " fine art" quote is veracious, we should see the result of this "fine-tuning" in the last Swimmer Plot with the last 14 evaluable patients treated.

10/14 Patients are CR(green dot) 72%CR.
  2/14 Patients are IR(yellow dot)   15%IR.
TR(total response) 72%+15%= 87% TR.
Ok..these numbers will change, but for now, could we agree that 72% CR is a very good proof that Dr.kulkarni "fine-tuning art" is working great.

This 72%CR "fine -tuning" mean that the number of red dot will stabelize, while the number of green dot will increase steadily.
Note: In the last Swimmer Plot , of the last 14 evaluable patients treated, only 2 are red dot, given time the total number of green dot could surpass the red dot.

For now, we have to sit tight and let the process run its course.

That is what I am going to do.
For the next few weeks, me and a group of friends are going to try "fine-tuning" our golf swing :).

Have a nice summer everybody.
Comment by N0taP00p on Jun 01, 2023 10:01am
@wildbird1 - how can your CR number be more than twice that published by Theralase. Even the KM curve projection doesn't cross 35% at 450 days.  
Comment by Eoganacht on Jun 01, 2023 1:16pm
wildbird is not writing about the CR rate at 450 days - he's writing about the CR results of the 3 patients at 270 days, the 7 at 180 days and the 4 at 90 days. 10 out of these 14 patients are CR - that's 71% You have to look at the recent swimmer's plot to appreciate what he's saying. The results at 270 days and below are predominantly CR.
Comment by N0taP00p on Jun 01, 2023 4:23pm
Thank you, Eoganacht. Appreciate the clarification. So the 450 day CR should only get better in about 6 months or so. 
Comment by Eoganacht on Jun 01, 2023 4:34pm
IMHO in 3 months the 450 day CR rate should be 36% and in 6 months it should be 41%
Comment by Donein25 on Jun 01, 2023 4:50pm
On top of that, if my math is correct...currently 91% of those with CR at 360 days continue as CR at 450 days.
Comment by DJDawg on Jun 01, 2023 5:20pm
Or if you look at those with an unbroken streak of CR from 90 to 360. 100% keep it.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250